Friday 6 November 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
87.28
1.42
+1.65%
Follow BNTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 3 | 2 | 2 |
| (6.01%) | (7.03%) | (9.53%) | (8.29%) | ||
| (5.22%) | (6.26%) | (8.24%) | (7.22%) | ||
ROIC |
(19.03%) | (22.28%) | (38.39%) | (34.28%) | |
Return on Tangible Assets |
(7.53%) | (8.44%) | (11.87%) | (10.18%) | |
Average Days of Receivables |
124.23 | 80.73 | 33.00 | 121.76 | |
Free Cash Flow per Share |
(1.35) | 2.22 | 1.98 | (2.10) | |
Free Cash Flow |
(326.41) | 563.49 | 500.72 | (524.10) | |
Capital Expenditures |
(842.33) | (282.16) | (257.85) | (246.89) | |
| Other line items | |||||
Cash ROIC |
(0.84%) | 1.43% | 1.31% | (1.39%) | |
Accounts Receivable Turnover |
2.37 | 3.59 | 3.17 | 3.00 | |
Accounts Payable Turnover |
1.36 | 1.42 | 1.13 | 1.30 | |
Inventory Turnover |
3.36 | 3.70 | 3.95 | 4.09 | |
Average Days of Payables |
304.20 | 277.61 | 367.17 | 317.11 | |
Days of Inventory on Hand |
62.96 | 61.47 | 57.12 | 39.34 | |
Tax Rate |
0.08 | 0.06 | 0.03 | 0.02 | |
Research and Development Expense of Revenue |
73.34% | 77.67% | 84.20% | 100.57% | |
Selling, General and Administrative Expense of Revenue |
21.76% | 23.68% | 27.49% | 31.59% | |
Share Based Compensation of Revenue |
2.82% | 3.02% | 2.66% | 2.54% | |
Interest Coverage |
(20.13) | (32.28) | (40.85) | (57.15) | |
Operating CF/Net income |
(0.40) | (0.58) | (0.38) | 0.16 | |
Depreciation/Fixed assets |
0.35 | 0.41 | 0.65 | 0.87 | |
Capex/Depreciation |
(1.94) | (0.53) | (0.33) | (0.25) | |
Revenue per Share |
13.43 | 12.61 | 11.92 | 10.94 | |
Operating CF per Share |
2.13 | 3.34 | 2.99 | (1.11) | |
Capex per Share |
(3.48) | (1.11) | (1.02) | (0.99) | |
Capex to Sales |
0.26 | 0.09 | 0.09 | 0.09 |
Columns are period end dates · fundamentals updated 5 Nov 2026